Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12183MR)

This product GTTS-WQ12183MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12183MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ326MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ3192MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ8392MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ2616MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ605MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ9052MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ6132MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ11356MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-551
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW